While Shashidhar et al.96 found that GPR56 activates several oncogenic signaling cascades, including the NF-κB pathway, Moreno et al.110 proposed that the receptor actually inhibits the NF-κB pathway and linked its high expression in GBM tissue with better survival outcome and less radioresistance. This evidence concerns the gene NFKB1 and glioblastoma.